remove_red_eye 558 Views
#Business And Medicine #Cardiology #Internal Medicine #Pharmacist
A novel implanted neuromodulation device substantially improved quality of life and functional capacity in heart failure with reduced ejection fraction (HFrEF) in the BeAT-AF study. Baroreflex stimulation with the Barostim Neo device also improved the key prognostic biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP) in the subset of patients with a baseline level of 1,600 pg/mL or less, reflecting less advanced heart failure.
Presenting the results at the Heart Rhythm Society meeting, Michael Zile, MD, of the Medical University of South Carolina in Charleston, said, "To our knowledge, this is the first successful pivotal trial of a device-based neuromodulation therapy in HFrEF patients.”
The device stimulates the baroreceptor with a 2 mm electrode that sits on the right carotid artery sinus and a lead extending to the generator.